Back to search

Article

Exenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonists

2026-07-22

Abstract excerpt

<h4>Objectives: </h4> Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that slows gastrointestinal (GI) motility. Whether exenatide produces clinically detectable GI motility slowing in real-world practice — and how this compares to other GLP-1 RAs — has not been systematically evaluated. We addressed this question using federated, electronic health record (EHR) data. Further, we present clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
870d1e31-b54c-5e1f-9b90-7fdba03ea543
DOI
10.20944/preprints202607.1605.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Exenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor AgonistsDOI 10.20944/preprints202607.1605.v1
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity
Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment.Semantic proximity
Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectivenessSemantic proximity
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Semantic proximity
Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity
Background Factors Involved in the Epidemiology of Functional Constipation in the Japanese PopulationSemantic proximity
The Safety and Efficacy of Ramosetron versus Psyllium for the Treatment of Fecal Incontinence (SERAFI) : Study protocol for a randomized trialSemantic proximity
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.Semantic proximity
Select a neighboring publication to make it the new centre.